chinasky : PI Coma by Cantech Letter - CGC - Buy Rating $4,25
Zandberg thinks recent investments from Canopy will bear fruit in the future, even if they don?t look so good on the balance sheet now.
?During the fourth quarter Canopy?s cost of production soared compared to the sale of product.,? he says. ?This was a direct result of the company?s phenotyping process where the production is focused on selecting new and improved strains rather than growing product for sale. We believe that this investment will pay dividends in a recreational market where the quality of experience will matter more than in the current medical marketplace. ?
Zandberg has a ?Buy? rating and one-year price target of $4.25 on Canopy Growth Corp. " ENDE Zitat